Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium-111 diethylenetriaminepentaacetic acid girentuximab
- Development stage
- Unknown
- Lead developer
- Heidelberg Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Indium-111 diethylenetriaminepentaacetic acid girentuximab** is a CAIX-targeted radioimmunoconjugate used as an investigational SPECT immunoimaging agent. It consists of the chimeric anti-carbonic anhydrase IX monoclonal antibody girentuximab, also called cG250 or G250, conjugated to diethylenetriaminepentaacetic acid and labeled with indium-111. Following intravenous administration, the antibody binds carbonic anhydrase IX on clear cell renal cell carcinoma cells, enabling localization of primary tumors and metastatic lesions by indium-111 gamma imaging. The agent has been used clinically for lesion visualization and dosimetry in clear cell renal cell carcinoma, including as an imaging companion to lutetium-177-girentuximab radioimmunotherapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10850349/))
- Other names
- 111In-cG250111In-DTPA-cG250111In-DTPA-G250111In-girentuximab
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on indium-111 diethylenetriaminepentaacetic acid girentuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium-111 diethylenetriaminepentaacetic acid girentuximab.